Emily Eddy was selected as one of the National Rural Health Association’s 2026 Fellows. Her work will focus on increasing ...
As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback